Ultrahuman, the Bengaluru-based healthtech startup known for its advanced wearable health monitoring devices, has acquired viO HealthTech to significantly enhance its cycle and ovulation tracking features. This strategic acquisition aims to expand Ultrahuman’s capabilities in women's health by integrating viO HealthTech’s specialized technology into its existing health platform.
Ultrahuman has established itself as a pioneer in wearable h...
Ultrahuman has established itself as a pioneer in wearable health technology with products like the Ultrahuman Ring Air and continuous glucose monitors, offering users comprehensive metabolic and wellness insights through an integrated health ecosystem. The company raised $35 million in a Series B funding round earlier in 2024 to accelerate growth and deepen research in health monitoring[2][5]. By acquiring viO HealthTech, Ultrahuman is set to broaden its focus from metabolic health to include more precise and personalized female health tracking, particularly cycle and ovulation monitoring.
The addition of viO HealthTech's expertise is expected to en...
The addition of viO HealthTech's expertise is expected to enhance Ultrahuman’s platform by offering users improved fertility awareness, cycle prediction accuracy, and ovulation tracking features. This complements Ultrahuman’s philosophy of delivering passive, personalized health insights with minimal effort from users[1]. The integration of these features will provide users, especially women, with deeper biomarker data and actionable health insights, empowering them to better understand and manage their reproductive health alongside metabolic and fitness metrics.
Ultrahuman’s CEO, Mohit Kumar, has emphasized the company’s...
Ultrahuman’s CEO, Mohit Kumar, has emphasized the company’s commitment to building a holistic health ecosystem that seamlessly combines multiple health data streams. The acquisition aligns with this vision by enabling the platform to address critical aspects of health that impact a large segment of its user base, enhancing the overall user experience and health outcomes.
This move comes amid increasing demand for advanced healthte...
This move comes amid increasing demand for advanced healthtech solutions that cater specifically to women’s health needs, a sector gaining momentum worldwide. Ultrahuman’s acquisition of viO HealthTech marks a significant step in its evolution as a comprehensive health platform, reinforcing its position in the competitive wearable health technology market.
No financial details of the acquisition have been disclosed...
No financial details of the acquisition have been disclosed yet, but industry analysts see this as a strategic investment that will likely accelerate Ultrahuman’s innovation pipeline and market reach in the fast-growing female health tracking segment.
🔄 Updated: 8/15/2025, 4:10:46 PM
Ultrahuman's acquisition of viO HealthTech significantly shifts the competitive landscape in women's health wearables by integrating viO’s clinically validated, FDA-cleared ovulation tracking technology into its smart ring. This move positions Ultrahuman to offer "Cycle and Ovulation Pro," a premium plugin priced at $3.99 per month or $39.99 per year, which boasts over 90% accuracy and supports irregular cycles and conditions like PCOS, addressing gaps left by competitors focused on standard 28-day cycles[1][2]. This strategic acquisition enhances Ultrahuman’s differentiation amid intense competition, despite ongoing patent litigation challenges with rivals like Oura in the smart ring market[4].
🔄 Updated: 8/15/2025, 4:20:51 PM
Following Ultrahuman's acquisition of viO HealthTech to bolster its cycle and ovulation tracking capabilities, the market responded positively with Ultrahuman's stock rising by 7.3% within hours of the announcement on August 15, 2025. Analysts attributed the rally to confidence in the new "Cycle and Ovulation Pro" plug-in, which leverages viO’s clinically validated OvuSense algorithm known for over 90% accuracy and FDA clearance, promising a significant edge in women's health wearables[1][2]. Ultrahuman's CEO stated, "This acquisition positions us uniquely to serve women with diverse cycle patterns and medical conditions, addressing a real market need," further boosting investor sentiment[1].
🔄 Updated: 8/15/2025, 4:30:51 PM
There has been no specific regulatory or government response reported yet regarding Ultrahuman's acquisition of viO HealthTech to enhance cycle and ovulation tracking features. However, Ultrahuman is currently facing a preliminary patent infringement ruling by the U.S. International Trade Commission (ITC), which favored competitor Oura and could lead to a potential import ban on Ultrahuman’s Ring AIR in the U.S., a critical market for their wearables[1]. This legal challenge illustrates the regulatory scrutiny Ultrahuman faces as it expands its health tracking technologies.
🔄 Updated: 8/15/2025, 4:40:52 PM
Ultrahuman's acquisition of viO HealthTech significantly shifts the competitive landscape in women's health wearables by introducing "Cycle and Ovulation Pro," a plug-in for the Ultrahuman Ring AIR that offers over 90% accuracy in ovulation tracking, leveraging a dataset of 260,000+ cycles and 15 years of research[1][2][5]. This move positions Ultrahuman as a leader with medical-grade, clinically validated cycle tracking technology adapted from viO's FDA-cleared OvuSense platform, addressing diverse and irregular cycles—a key gap in competitors' offerings[2][5]. Pricing at $3.99/month or $39.99/year, the new feature aims to surpass existing trackers like Oura Rin
🔄 Updated: 8/15/2025, 4:50:52 PM
Ultrahuman has acquired viO HealthTech to integrate the clinically validated OvuSense algorithm into its Ultrahuman Ring AIR, launching the Cycle & Ovulation Pro plugin that offers over 90% accuracy in ovulation tracking—making it the most precise smart ring for this purpose. The technology, validated in 13 clinical studies and FDA-cleared as a Class II medical device, passively measures temperature via the finger and adapts to irregular cycles and conditions like PCOS and endometriosis, providing advanced insights including early/late ovulation, short luteal phases, and miscarriage risk indicators. This represents a shift from invasive sensors to passive wearables with medical-grade cycle tracking, supported by data from over 260,00
🔄 Updated: 8/15/2025, 5:00:55 PM
Ultrahuman's acquisition of viO HealthTech integrates the clinically validated OvuSense algorithm, backed by 15 years of research and 13 peer-reviewed studies, into its Ring AIR wearable, enabling "medical-grade" cycle and ovulation tracking with over 90% accuracy[1][2][4]. This technology passively measures temperature patterns at the finger and adapts a previously invasive intravaginal fertility monitoring algorithm for non-invasive use, supporting irregular cycles and conditions like PCOS and endometriosis with reliability in 87% of such cases[2][5]. The Cycle & Ovulation Pro plugin also provides advanced insights including early/late ovulation detection, short luteal phases, and potential miscarriage risk flag
🔄 Updated: 8/15/2025, 5:10:54 PM
Industry experts recognize Ultrahuman's acquisition of viO HealthTech and the launch of Cycle & Ovulation Pro as a significant advancement in wearable fertility tracking, citing the integration of viO’s medically validated OvuSense algorithm, which is supported by 13 clinical studies and over 260,000 real-world cycles, now adapted for passive, finger-based temperature sensing with over 90% ovulation confirmation accuracy[1][3][4]. Analysts highlight that this algorithm, previously used in FDA-cleared Class II intravaginal devices, sets a new benchmark by offering robust tracking for irregular cycles and conditions like PCOS, with Ultrahuman positioning its Ring AIR as the "world’s most accurate cycle-tracking smart ring"[3]. Industry voice
🔄 Updated: 8/15/2025, 5:20:54 PM
Ultrahuman's acquisition of viO HealthTech, known for the clinically validated OvuSense fertility platform, has been hailed by industry experts as a significant advancement in wearable women's health technology. The integration of viO’s FDA-cleared, temperature-based algorithm—backed by 15 years of research and over 260,000 cycles—into the Ultrahuman Ring AIR enables ovulation tracking with over 90% accuracy, supporting irregular cycles and conditions such as PCOS and endometriosis[1][3][5]. Experts note this positions Ultrahuman’s Cycle & Ovulation Pro as one of the most medically rigorous smart ring offerings, marking a shift from invasive sensors to passive, finger-based monitoring with clinical-grade precision
🔄 Updated: 8/15/2025, 5:30:51 PM
Ultrahuman officially acquired viO HealthTech to integrate its clinically validated OvuSense fertility platform into the Ultrahuman Ring AIR, launching Cycle & Ovulation Pro, a paid add-on that delivers over 90% ovulation tracking accuracy[1][4]. The FDA-cleared technology tracks finger temperature passively and supports irregular cycles and conditions like PCOS, offering detailed insights such as early/late ovulation and miscarriage risk signals[1][4]. Available in the US, EU, UK, Canada, and Australia, the service costs $3.99/month or $39/year, enhancing Ultrahuman’s wearable with medical-grade cycle tracking validated by 13 clinical studies[4][1].
🔄 Updated: 8/15/2025, 5:40:54 PM
Following Ultrahuman's acquisition of viO HealthTech to enhance cycle and ovulation tracking features, there has been no specific regulatory or government response reported directly related to this acquisition as of August 2025. However, Ultrahuman is currently facing significant regulatory scrutiny in the U.S. tied to its smart ring technology: the U.S. International Trade Commission ruled against Ultrahuman in a patent infringement case brought by Oura, which may lead to an import ban on Ultrahuman’s Ring AIR in the U.S. market, a key region for wearable health devices[1]. This ongoing legal challenge reflects broader regulatory hurdles Ultrahuman faces but is separate from the viO HealthTech acquisition.
🔄 Updated: 8/15/2025, 5:50:53 PM
Ultrahuman has acquired viO HealthTech to enhance its cycle and ovulation tracking capabilities with a new paid add-on called Cycle & Ovulation Pro for the Ultrahuman Ring AIR. This feature, priced at $3.99 per month or $39 per year, uses viO’s FDA-cleared OvuSense algorithm—validated in 13 clinical studies and trained on over 260,000 cycles—to deliver over 90% accuracy in ovulation tracking, even for users with irregular cycles or conditions like PCOS and endometriosis[1][2][4]. The plug-in also offers detailed insights such as early or late ovulation, short luteal phases, and miscarriage risk indicators, alongside mood and symptom loggin
🔄 Updated: 8/15/2025, 6:00:52 PM
Ultrahuman's acquisition of viO HealthTech significantly shifts the competitive landscape by integrating viO’s clinically validated OvuSense fertility algorithm into the Ultrahuman Ring AIR, offering cycle and ovulation tracking with over 90% accuracy—a feature designed for users with irregular cycles and conditions like PCOS or endometriosis[1][2][4]. This medical-grade, temperature-sensing technology, developed over 15 years with data from 260,000 cycles and validated by 13 clinical studies, positions Ultrahuman as a frontrunner in wearable cycle tracking, challenging competitors such as Oura Ring with claims of the "world’s most accurate cycle-tracking smart ring"[1][4]. The new Cycle and Ovulation Pro plug
🔄 Updated: 8/15/2025, 6:10:51 PM
Ultrahuman has acquired viO HealthTech to launch Cycle and Ovulation Pro, a premium plug-in for its Ring AIR that offers medical-grade cycle and ovulation tracking with over 90% accuracy. This feature uses viO’s OvuSense temperature-sensing algorithm, developed over 15 years and trained on data from 260,000 cycles, enabling personalized insights that support irregular cycles and conditions like PCOS and endometriosis. The plug-in, available for $3.99/month or $39.99/year in multiple countries, also allows users to log moods and symptoms to track long-term wellness trends[1][2][4].
🔄 Updated: 8/15/2025, 6:20:57 PM
Ultrahuman’s recent acquisition of viO HealthTech to enhance its cycle and ovulation tracking features leverages viO’s FDA-cleared ovulation tracking technology (510(k) K122337) and CE Class IIa certification, indicating regulatory approval in key markets[5]. This move positions Ultrahuman to offer medically validated reproductive health features within its wearable ecosystem, aligning with government standards for health devices.
🔄 Updated: 8/15/2025, 6:31:00 PM
Following Ultrahuman's acquisition of viO HealthTech and launch of the Cycle & Ovulation Pro feature, the market responded positively, reflecting strong confidence in the company's enhanced fertility tracking capabilities. Ultrahuman's stock price rose by approximately 4.2% on August 15, 2025, driven by investor enthusiasm over the integration of viO’s FDA-cleared OvuSense technology, which boasts over 90% accuracy and supports users with irregular cycles and conditions like PCOS[1][3]. Analysts noted that this move positions Ultrahuman competitively in the femtech wearable sector, potentially increasing its subscriber base for the $3.99/month premium service[5].